Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from CSL ( (AU:CSL) ) is now available.
CSL has announced its financial results for the half year ending December 31, 2024, showing a 5% increase in total revenue to US$8.483 billion and a 6% increase in net profit after tax (NPAT) to US$2.007 billion. These results reflect the company’s robust performance and strategic focus on enhancing shareholder value. The interim dividend is set at US$1.30 per security, unfranked, underscoring CSL’s strong operational execution and its commitment to returning capital to shareholders.
More about CSL
CSL is a leading global biotechnology company based in Melbourne, Australia. The company specializes in the development and delivery of innovative medicines and vaccines, focusing on areas such as immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapies. CSL is known for its extensive research and development efforts and its commitment to addressing unmet medical needs across various markets.
YTD Price Performance: 7.32%
Average Trading Volume: 733
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $81.73B
See more insights into CSL stock on TipRanks’ Stock Analysis page.
